News
Jay Bhattacharya will become the latest leader of the CDC on an acting basis, days after Jim OâNeill stepped aside.
FEATURED STORIES
PitchBookâs 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressedâand thereâs more to come in 2026.
Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The FDAâs refusal to review Modernaâs mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.
THE LATEST
FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDAâs priorities, including accelerating cures and the rapid deployment of artificial intelligence.
Instead of homing in on PSMAâcurrently the most validated target in prostate cancerâBMS and Philochem will instead collaborate on an early-stage molecule that binds to a novel marker called ACP3.
The companyâs intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.
The American Medical Association is also urging an âimmediate reversalâ of the HHS Secretaryâs decision to oust all 17 members of the CDCâs vaccine advisory board.
The layoffs will heavily affect Vertexâs operations in Rhode Island, where the biotech will consolidate three facilities into one.
Guggenheim Partners called Insmedâs Phase IIb readout âimpressive across the board,â with an efficacy profile that positions TPIP to be best-in-class in pulmonary arterial hypertension.
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharmaâs amylin efforts underwhelmed investors.
The deal is Lillyâs second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to develop long-acting versions of molecules against GLP-1 and other incretins.
HHS Secretary Robert F. Kennedy Jr. made waves this week, firing the remaining members of the CDCâs Advisory Committee on Immunization Practices; Metseraâs amylin drug produced weight loss of 8.4% at 36 days; and FDA leaders gathered last week to discuss the future of cell and gene therapy, a sector that has been in turmoil since the ousting of CBER Chief Peter Marks.
Some companiesâ preferences for people who already have industry experience and the tough job market are among the hurdles those just starting out in biopharma must navigate, two recruitment experts told BioSpace.